

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

Rec'd PCT/PTQ 20 DEC 2004

PCT/SE 03 / 0 1 0 8 0

REC'D 10 JUL 2003

WIPO PCT

Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande AstraZeneca AB, Södertälje SE
Applicant (s)

(21) Patentansökningsnummer 0201977-6
Patent application number

(86) Ingivningsdatum 2002-06-24
Date of filing

Stockholm, 2003-06-30

För Patent- och registreringsverket
For the Patent- and Registration Office


Görel Gustafsson

Avgift
Fee

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

PATENT- OCH
REGISTRERINGSVERKET
SWEDEN

Postadress/Address
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

BEST AVAILABLE COPY

NOVEL COMPOUNDS


The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of such inhibitors.

BACKGROUND OF THE INVENTION

Cathepsin S is a member of the papain superfamily of cysteine proteases which also encompasses Cathepsins B, H, L, O and K. Cathepsin S plays a key role in the processing of invariant chain in MHC class II complexes allowing the complex to associate with antigenic peptides. MHC class II complexes are then transported to the surface of the cell for presentation to effector cells such as T cells. The process of antigen presentation is a fundamental step in initiation of the immune response. In this respect inhibitors of cathepsin S could be useful agents in the treatment of inflammation and immune disorders such as, but not limited to, asthma, rheumatoid arthritis, multiple sclerosis and Crohn's disease. Cathepsin S has also been implicated in a variety of other diseases involving extracellular proteolysis such as the development of emphysema in COPD through degradation of elastin and in Alzheimers disease.

Other Cathepsins notably K and L have been shown to degrade bone collagen and other bone matrix proteins. Inhibitors of these cysteine proteases would be expected to be useful in the treatment of diseases involving bone resorption such as osteoporosis.

The present invention therefore provides a compound of formula (I)



(I)

5 in which:

A is a 6-membered ring optionally containing a double bond and optionally containing an oxygen atom or NR group in the ring;

R is hydrogen or C₁₋₆ alkyl;

10

R¹ and R² are independently, C₁₋₆ alkyl or C₃₋₆ cycloalkyl both of which can optionally contain one or more O, S or NR³ groups, or R¹ and R² together with the nitrogen atom to which they are attached form a 3,4-dihydroisoquinoline ring or a 5- or 6-membered saturated ring optionally containing a further O, S or N atom and optionally substituted by

15

a group -(CH₂)_p-R⁶ where p is 0 to 3 and R⁶ is C₁₋₆ alkyl, CONR⁷R⁸ where R⁷ and R⁸ are independently hydrogen, C₁₋₆ alkyl which can optionally contain one or more O, S or NR³ groups, or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR³ group;

or R⁶ is a 4 to 7-membered saturated ring optionally containing one or more O, S or N

20

atoms, or an aryl or heteroaryl group containing one to four heteroatoms selected from O, S or N, the saturated ring, aryl and heteroaryl groups all being optionally substituted by

halogen, amino, hydroxy, cyano, nitro, carboxy, CONR⁷R⁸, SO₂NR⁷R⁸, SO₂R³, trifluoromethyl, NHSO₂R³, NHCOR³, C₁₋₆ alkyl, C₁₋₆ alkoxy, SR³ or NR⁹R¹⁰ where R⁹ and R¹⁰ are independently hydrogen, C₁₋₆ alkyl or together with the nitrogen atom to which they

25

are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR³ group;

R³ is hydrogen or C₁₋₆ alkyl;

30

R⁴ is hydrogen or C₁₋₆ alkyl;

R^5 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl both of which can optionally contain one or more O, S or NR^3 groups or R^5 is aryl or a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from O, S or N, the aryl and heteroaryl groups all being optionally substituted by halogen, amino, hydroxy, cyano, nitro, carboxy, $CONR^7R^8$, $SO_2NR^7R^8$, SO_2R^3 , trifluoromethyl, $NHSO_2R^3$, $NHCOR^3$, C_{1-6} alkyl, C_{1-6} alkoxy, SR^3 or NR^9R^{10} where R^9 and R^{10} are independently hydrogen, C_{1-6} alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR^3 group;

or R^4 and R^5 together form a 5- or 6-membered saturated ring optionally containing a further O, S or NR^3 group and optionally substituted by, C_{1-6} alkyl;

and pharmaceutically acceptable salts or solvates thereof.

In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear or branched. Aryl groups include phenyl and naphthyl. Heteroaryl groups include 5- or 6-membered, 5,6- or 6,6-fused aromatic rings containing one or more heteroatoms selected from N, S, O. Examples include pyridine, pyrimidine, pyrazine, pyridazine, thiazole, oxazole, pyrazole, imidazole, furan and thiophene, quinoline, isoquinoline, benzimidazole, benzofuran, benzothiophene, indole.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.

Suitably A is a 6-membered ring optionally containing a double bond and optionally containing an oxygen atom or NR group in the ring where R is hydrogen or C_{1-6} alkyl. A double bond can be present in any suitable position of the ring A. An oxygen atom or NR group can be present in any suitable position of the ring A, in addition to a double bond if desired. Preferably A is a cyclohexane ring.

Preferably R^1 and R^2 together with the nitrogen atom to which they are attached form an unsubstituted morpholine ring or a piperidine or piperazine ring substituted by a group —

$(CH_2)_p-R^6$ where p and R^6 are as defined above. Preferably p is 0 and R^6 is aryl or heteroaryl optionally substituted as defined above.

Preferably R^3 is hydrogen.

Preferably R^4 is hydrogen.

Preferably R^5 is hydrogen, phenyl optionally substituted by C_{1-6} alkyl or C_{1-6} alkoxy

Preferred compounds of the invention include:

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(morpholin-4-ylcarbonyl)cyclohexanecarboxamide,

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-[[4-(4-fluorobenzyl)piperazin-1-yl]carbonyl]cyclohexane carboxamide,

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)cyclohexane carboxamide,

(±) Trans-N-(cyanomethyl)-2-[[4-(4-fluorobenzyl)piperazin-1-yl]carbonyl]cyclohexanecarboxamide,

(±) Trans-N-[cyano(2-methoxyphenyl)methyl]-2-[(4-methylpiperazin-1-yl)carbonyl]cyclohexanecarboxamide,

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexane carboxamide,


(1R,2R)-N-(4-Cyano-1-methylpiperidin-4-yl)-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexane carboxamide,

(1R,2R)-N-(4-Cyanotetrahydro-2H-pyran-4-yl)-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexane carboxamide,


(1R,2R)-N-[(1S)-1-cyano-3-methoxypropyl]-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexanecarboxamide,

and pharmaceutically acceptable salts thereof.

The present invention further provides a process for the preparation of a compound of formula (I) which comprises reaction of a compound of general formula (II) with a dehydrating agent (e.g. phosphorous oxychloride)



(II)




(III)


Compounds of formula (II) may be prepared from compounds of formula (III) by activation of the acid with an appropriate coupling agent or formation of acid chloride followed by reaction with an amine $\text{HNR}^3(\text{CR}^4\text{R}^5)\text{CONH}_2$ where R^3 , R^4 and R^5 are defined in formula (I)

reaction of a compound of general formula (III) by activation of the acid group with an appropriate coupling agent or formation of acid chloride followed by reaction with an amine $\text{HNR}^3(\text{CR}^4\text{R}^5)\text{CN}$ where R^3 , R^4 and R^5 are defined in formula (I)

reaction of a compound of general formula (IV), where $\text{X} = \text{CN}$ or CONH_2 , by activation of the acid group with an appropriate coupling agent or formation of acid chloride followed by reaction with an amine HNR^1R^2 where R^1 and R^2 are defined in formula (I)



(IV)




(V)

Compounds of general formula (III) and (IV) may be prepared from compound of general formula (V) by reaction with an amine of general formula $\text{HNR}^3(\text{CR}^4\text{R}^5)\text{CN}$, $\text{HNR}^3(\text{CR}^4\text{R}^5)\text{CONH}_2$ where R^3 , R^4 and R^5 are defined in formula (I) or HNR^1R^2 where R^1 and R^2 are defined in formula (I).

5

Compounds of general formula (III) and (IV) may also be prepared from a compound of general formula (VI) by activation of the acid group with an appropriate coupling agent or formation of acid chloride followed by reaction with an amine of general formula $\text{HNR}^3(\text{CR}^4\text{R}^5)\text{CN}$, $\text{HNR}^3(\text{CR}^4\text{R}^5)\text{CONH}_2$ where R^3 , R^4 and R^5 are defined in formula (I) or HNR^1R^2 where R^1 and R^2 are defined in formula (I) followed by hydrolysis of the ester.

10



15

According to a further feature of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use as a therapeutic agent.

According to a further feature of the present invention there is provided a method for producing inhibition of a cysteine protease in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof.

20

The invention also provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use as a medicament; and the use of a compound of the formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the inhibition of a cysteine protease in a warm blooded animal, such as man.

25

In particular the invention provides the use of a compound of the formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the inhibition of Cathepsin S in a warm blooded animal, such as man. In order to use a compound of the formula (I) or a pharmaceutically acceptable salt thereof for the therapeutic treatment of mammals including humans, in particular in the inhibition of a cysteine protease, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 100 mg and 1 g of the compound of this invention.

In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.

Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of 1 mgkg^{-1} to 100 mgkg^{-1} of the compound, preferably in the range of 5 mgkg^{-1} to 20 mgkg^{-1} of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), or a pharmaceutically-acceptable salt thereof (hereafter compound X), for therapeutic or prophylactic use in humans:

(a)

<u>Tablet I</u>	<u>mg/tablet</u>
Compound X.	100
Lactose Ph.Eur.	179
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

(b)

<u>Tablet II</u>	<u>mg/tablet</u>
Compound X	50
Lactose Ph.Eur.	229
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

5

(c)

<u>Tablet III</u>	<u>mg/tablet</u>
Compound X	1.0
Lactose Ph.Eur.	92
Croscarmellose sodium	4.0
Polyvinylpyrrolidone	2.0
Magnesium stearate	1.0

(d)

<u>Capsule</u>	<u>mg/capsule</u>
Compound X	10
Lactose Ph.Eur.	389
Croscarmellose sodium	100
Magnesium stearate	1.

(e)

<u>Injection I</u>	<u>(50 mg/ml)</u>
Compound X	5.0% w/v
Isotonic aqueous solution	to 100%

Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl β cyclodextrin may be used to aid formulation.

5 Note

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

10 The following examples illustrate the invention.

Example 1

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(morpholin-4-ylcarbonyl)cyclohexanecarboxamide

(i) (1R,2R)-2-([Cyano(2-methoxyphenyl)methylamino]carbonyl)cyclohexanecarboxylic acid

A mixture of (3aR,7aR)-hexahydro-2-benzofuran-1,3-dione (3.64g), N,N-diisopropylethylamine (7.63g) and (\pm) 2-(2-methoxyphenyl)aminoacetonitrile

hydrochloride (4.7g) in tetrahydrofuran (50ml) was stirred at room temperature for 6 hours. The solvent was removed under reduced pressure and the residue dissolved in water.

The cooled (0°C) aqueous solution was acidified by dropwise addition of dilute aqueous hydrochloric acid and the resultant mixture extracted with ethyl acetate. The organic layer was washed with aqueous brine, dried (MgSO₄), and evaporated under reduced pressure.

The residue was purified by titration with diethyl ether (100ml) followed by ethyl acetate (3 x 30ml). Yield 1.5g

MS: APCI(+ve) 317(M+1)

(ii) (1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(morpholin-4-ylcarbonyl)cyclohexanecarboxamide

A solution of the product from step (i) (0.35g), morpholine (0.14g), N,N-diisopropylethylamine (0.36g) and 1-hydroxybenzotriazole (0.22g) in tetrahydrofuran (10ml) was treated with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.32g) and stirred for 6 hours at room temperature. The mixture was partitioned between ethyl acetate and aqueous brine, the organics dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by chromatography on silica, eluting with a mixture of ethyl acetate (75%) and isohexane (25%). Yield 0.05g

MS: APCI(+ve) 386(M+1)

¹H NMR: (CDCl₃) δ 7.37-7.29(2H, m), 6.96-6.92(3H, m), 6.07(1H, d), 3.97(3H, s), 3.53-3.28(6H, m), 3.16-3.12(2H, m), 2.77-1.63(2H, m), 1.95(1H, d), 1.84-1.58(4H, m), 1.46-1.26(3H, m).

5 Examples 2 and 3

Examples 2 and 3 were prepared according to the general method of example 1 using the appropriate amines

Example 2

10 (1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-[[4-(4-fluorobenzyl)piperazin-1-yl]carbonyl]cyclohexane carboxamide.

MS: APCI(+ve) 493(M+1)

¹H NMR: (CDCl₃) δ 7.37-7.21(4H, m), 7.03-6.92(5H, m), 6.06(1H, d), 3.96(3H, s), 3.36-3.31(5H, m), 3.20-3.10(1H, m), 2.73-2.66(2H, m), 2.29-2.25(2H, m), 2.20-2.12(1H, m),
15 1.95-1.60(6H, m), 1.40-1.20(3H, m).

Example 3

20 (1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl]cyclohexane carboxamide

MS: APCI(+ve) 432(M+1)

¹H NMR: (DMSO-d₆) δ 9.06-8.97(1H, m), 7.42-7.32(2H, m), 7.23-6.93(6H, m), 6.03-5.93(1H, m), 4.73-4.38(2H, m), 3.81, 3.73(3H, 2 x s), 3.80-3.40(2H, m), 3.00-2.55(4H, m),
25 1.92-1.69(4H, m), 1.38-1.17(4H, m).

Example 4

(±) Trans-N-(cyanomethyl)-2-[[4-(4-fluorobenzyl)piperazin-1-yl]carbonyl]cyclohexanecarboxamide

A mixture of (\pm)trans-1,2-cyclohexanedicarboxylic anhydride (0.4g), N,N-diisopropylethylamine (0.34g) and 1-(4-fluorobenzyl)piperazine (0.5g) in tetrahydrofuran (15ml) was stirred at room temperature for 18 hours. At the end of this time the reaction mixture was treated with further N,N-diisopropylethylamine (0.34g) followed by aminoacetonitrile hydrochloride (0.36g), 1-hydroxybenzotriazole (0.53g) and finally N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.75g). The mixture was stirred for 18 hours and subsequently partitioned between ethyl acetate and aqueous sodium bicarbonate, the organics dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by chromatography on silica, eluting with a mixture of triethylamine (0.6%), methanol (2%) and dichloromethane (97.4%). Yield 0.045g

MS: APCI(+ve) 387(M+1)

¹H NMR: (DMSO-d₆) δ 8.46(1H, t), 7.36-7.31(2H, m), 7.17-7.11(2H, m), 4.03(2H, d), 3.50-3.35(6H, m), 2.90-2.80(1H, m), 2.41-2.24(4H, m), 1.80-1.77(1H, m), 1.73-1.65(3H, m), 1.32-1.15(4H, m).

Example 5

(\pm) Trans-N-[cyano(2-methoxyphenyl)methyl]-2-[(4-methylpiperazin-1-yl)carbonyl]cyclohexanecarboxamide

(i) (\pm) Trans-2-([cyano(2-methoxyphenyl)methyl]amino)carbonyl cyclohexanecarboxylic acid

A mixture of (\pm) trans-1,2-cyclohexanedicarboxylic anhydride (5.0g), N,N-diisopropylethylamine (5.03g) and (\pm) 2-(2-methoxyphenyl)aminoacetonitrile hydrochloride (3.87g) in tetrahydrofuran (50ml) was stirred at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue dissolved in water. The cooled (0°C) aqueous solution was acidified by dropwise addition of dilute aqueous hydrochloric acid and the resultant mixture extracted with ethyl acetate. The organic layer was washed with aqueous brine, dried (MgSO₄), and evaporated under reduced pressure. The residue was purified by titration with ethyl acetate (2 x 30ml). Yield 0.53g

MS: APCI(+ve) 317(M+1)

(ii) (1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-[(4-methylpiperazin-1-yl)carbonyl]cyclohexane carboxamide

A solution of the product from step (i) (0.38g), 1-methylpiperazine (0.18g), N,N-diisopropylethylamine (0.23g) and 1-hydroxybenzotriazole (0.24g) in 1-methyl-2-pyrrolidinone (10ml) was treated with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (0.35g) and stirred for 4 hours at room temperature. The mixture was partitioned between ethyl acetate and aqueous sodium bicarbonate, the organics washed with aqueous brine (x3), dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by chromatography on silica, eluting with a mixture of triethylamine (0.4%), methanol (4%) and dichloromethane (95.6%) followed by titration of the resultant product with diethyl ether. Yield 0.035g

MS: APCI(+ve) 399(M+1)

¹H NMR: (DMSO-d₆) δ 8.99(1H, d), 7.44-7.38(2H, m), 7.09(1H, d), 7.00(1H, t), 6.00(1H, d), 3.85(3H, s), 3.44-3.40(2H, m), 2.90-2.82(1H, m), 2.70-2.62(1H, m), 2.24-2.21(2H, m), 2.11-2.08(4H, m), 2.03-2.01(1H, m), 1.87(1H, d), 1.76-1.66(3H, m), 1.36-1.17(4H, m).

Example 6

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-1-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexane carboxamide

(i) Methyl (1R,2R)-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexanecarboxylate

A solution of (1R,2R)-cyclohexane 1,2-dicarboxylic acid mono-methyl ester (1.0g) in 1-methyl-2-pyrrolidinone (20ml) was treated with N,N-diisopropylethylamine (1.73g)

followed by 1-(4-fluorophenyl)piperazine (1.45g) and 1-hydroxybenzotriazole (1.09g). The resultant mixture was then treated with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.55g) and stirred for 18 hours at room temperature. The mixture was partitioned between ethyl acetate and water, the organics washed with water (x3), dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by chromatography on silica, eluting with a mixture of ethyl acetate (45%) and isohexane (55%). Yield 1.4g

MS: APCI(+ve) 349(M+1)

(ii) (1R,2R)-2-([4-(4-Fluorophenyl)piperazin-1-yl]carbonyl)cyclohexanecarboxylic acid

A solution of the product from step (i) (1.1g) in methanol (40ml) was treated with a solution of sodium hydroxide (0.25g) in water (20ml) and the resultant mixture heated at 50°C for 24 hours. The solvent was removed under reduced pressure and the residue dissolved in water and washed with diethyl ether, the aqueous layer was acidified by addition of glacial acetic acid and extracted with ethyl acetate (x2). The combined ethyl acetate layers were washed with aqueous brine, dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by titration with diethyl ether. Yield 0.9g

MS: APCI(+ve) 335(M+1)

(iii) (1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-([4-(4-fluorophenyl)piperazin-1-yl]carbonyl)cyclohexanecarboxamide

A solution of the product from step (iii) (0.35g) in dichloromethane (10ml) at 0°C was treated with (±) 2-(2-methoxyphenyl)aminoacetonitrile hydrochloride (0.25g) and N,N-diisopropylethylamine (0.54g) followed by O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.44g). The mixture was stirred at 0°C for 1 hour and then at room temperature for 18 hours. The mixture was partitioned between ethyl acetate and water, the organics washed with water, dried (MgSO₄) and evaporated

under reduced pressure. The residue was purified by chromatography on silica, eluting with a mixture of ethyl acetate (67%) and isohexane (33%). Yield 0.27g

MS: APCI(+ve) 479(M+1)

5 ¹H NMR: (CDCl₃) δ 7.39-7.23(2H, m), 7.01-6.77(7H, m), 6.06-5.97(1H, m), 3.97-3.95(4H, m), 3.80-3.36(4H, m), 3.19-3.15(1H, m), 3.10-2.47(5H, m), 1.98-1.75(3H, m), 1.65-1.26(4H, m).

Examples 7 and 8

10 Examples 7 and 8 were prepared according to the general method of example 6 step (iii) using the appropriate amines.

Example 7

15 (1R,2R)-N-(4-Cyanotetrahydro-2H-pyran-4-yl)-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexane carboxamide

MS: APCI(+ve) 443(M+1)

¹H NMR: (CDCl₃) δ 7.00-6.94(2H, m), 6.89-6.85(2H, m), 6.32(1H, s), 3.90-3.80(3H, m), 3.78-3.59(5H, m), 3.16-3.12(1H, m), 3.09-3.00(3H, m), 2.92-2.86(1H, m), 2.70-2.64(1H, m), 2.46-2.42(1H, m), 2.22-2.19(1H, m), 1.94-1.82(6H, m), 1.69-1.63(1H, m), 1.49-1.30(3H, m).

Example 8

25 (1R,2R)-N-(4-Cyano-1-methylpiperidin-4-yl)-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexane carboxamide

MS: APCI(+ve) 456(M+1)

¹H NMR: (CDCl₃) δ 7.00-6.94(2H, m), 6.90-6.85(2H, m), 6.20(1H, s), 3.90-3.85(1H, m), 3.80-3.75(1H, m), 3.70-3.60(2H, m), 3.18-3.13(1H, m), 3.09-3.04(3H, m), 2.91-2.85(1H, m)

m), 2.73-2.61(3H, m), 2.49-2.35(3H, m), 2.29(3H, s), 2.28-2.22(1H, m), 1.90-1.81(6H, m), 1.70-1.60(1H, m), 1.50-1.32(3H, m).

Example 9

(1R,2R)-N-[(1S)-1-cyano-3-methoxypropyl]-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexanecarboxamide

(i) N-2-(tert-butoxycarbonyl)-O-methyl-L-homoserinamide

A solution of Boc-O-methyl-L-homoserine (7.75g) in dichloromethane (100ml) was treated with carbonyldiimidazole (6.46g) and the mixture stirred for 1h at room temperature. At the end of this time concentrated aqueous ammonia (20ml) was added and stirring continued for a further 40min. The reaction mixture was washed with water followed by dilute aqueous sodium hydroxide and then with aqueous brine before being dried (MgSO₄) and evaporated under reduced pressure. Yield 2.9g

¹H NMR: (DMSO-d₆) δ 7.22(1H, s), 6.94(1H, s), 6.76(1H, d), 3.94-3.88(1H, m), 3.20(3H, s), 1.87-1.83(1H, m), 1.69-1.64(1H, m), 1.38(9H, s).

(ii) O-Methyl-L-homoserinamide hydrochloride

A solution of the product from step (i) (2.9g) in 1,4-dioxane (30ml) was treated with a 4.0 molar solution of HCl in 1,4-dioxane (15ml) and the mixture allowed to stand for 18h at room temperature. The resultant precipitate was filtered off and washed with diethylether. Yield 1.84g

¹H NMR: (DMSO-d₆) δ 8.20(3H, s), 7.94(1H, s), 7.54(1H, s), 3.76(1H, s), 3.46-3.37(2H, m), 3.24(3H, s), 2.05-1.90(2H, m).

(iii) (1R,2R)-N-[(1S)-1-Carboxamide-3-methoxypropyl]-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexanecarboxamide

A solution of the product from step (ii) (0.36g) in 1-methyl-2-pyrrolidinone (15ml) was treated with N,N-diisopropylethylamine (0.93g) followed by (1R,2R)-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexanecarboxylic acid (prepared as described in Example 6, step (ii)) (0.6g). The reaction mixture was cooled to 0°C and treated with O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.75g).

The mixture was stirred at 0°C for 1h and then at room temperature for 18h. The mixture was partitioned between ethyl acetate and water, the organics washed with water (x3), dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by trituration with diethylether. Yield 0.40g

MS: APCI(+ve) 449(M+1)

(iv) (1R,2R)-N-[(1S)-1-Cyano-3-methoxypropyl]-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexanecarboxamide

Oxalyl chloride (0.34g) was added dropwise to N,N-dimethylformamide (10ml) at 0°C and the mixture stirred at this temperature for 5 minutes. Pyridine (0.42g) was then added and stirring continued for a further 5 minutes. At the end of this time the mixture was treated dropwise with a solution of the product of step (iii) (0.59g) in N,N-dimethylformamide (5ml). After stirring for 2 hours at 0°C the mixture was partitioned between ethyl acetate and water, the organics washed with water, dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by chromatography on silica, eluting with a mixture of ethyl acetate (80%) and isohexane (20%). Yield 0.21g

MS: APCI(+ve) 431(M+1)

¹H NMR: (DMSO-d₆) δ 8.57(1H, d), 7.08-7.03(2H, m), 6.99-6.94(2H, m), 4.71(1H, q), 3.70-3.58(3H, m), 3.50-3.47(1H, m), 3.37-3.30(2H, m), 3.17(3H, s), 3.08-3.00(3H, m), 2.96-2.89(2H, m), 2.57-2.49(1H, m), 1.98-1.68(6H, m), 1.38-1.20(4H, m).

Measurement of Cathepsin S activity.

QFRET Technology (Quenched Fluorescent Resonance Energy Transfer) was used to measure the inhibition by test compounds of Cathepsin S-mediated cleavage of the synthetic peptide Z-Val-Val-Arg-AMC. Compounds were screened at five concentrations in duplicate and the pIC₅₀ values reported.

Synthetic substrate, 20μM [final]Z-Val-Val-Arg-AMC in phosphate buffer were added to a 96 well black Optiplate. The assay plates were pre-read for compound auto fluorescence on SpectraMax Gemini at 355nm excitation and 460nm emission. 250pM [final] rHuman Cathepsin S in phosphate buffer was added and incubated for 2h at room temperature on


the SpectraMax Gemini, taking readings every 20min at 355nm excitation and 460nm emission.

Activity Based template (5PTB-8) used the auto fluorescent corrected data to calculate the percentage inhibition for each compound concentration using the relevant plate controls.

This data was used to construct inhibition curves and pIC_{50} estimated by non-linear regression using a 4 parameter logistic model.

CLAIMS

1. A compound of formula (I):



(I)

in which:

A is a 6-membered ring optionally containing a double bond and optionally containing an oxygen atom or NR group in the ring;

R is hydrogen or C₁₋₆ alkyl;

15

R¹ and R² are independently, C₁₋₆ alkyl or C₃₋₆ cycloalkyl both of which can optionally contain one or more O, S or NR³ groups, or R¹ and R² together with the nitrogen atom to which they are attached form a 3,4-dihydroisoquinoline ring or a 5- or 6-membered saturated ring optionally containing a further O, S or N atom and optionally substituted by a group -(CH₂)_p-R⁶ where p is 0 to 3 and R⁶ is C₁₋₆ alkyl, CONR⁷R⁸ where R⁷ and R⁸ are independently hydrogen, C₁₋₆ alkyl which can optionally contain one or more O, S or NR³ groups, or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR³ group;

20

or R⁶ is a 4 to 7-membered saturated ring optionally containing one or more O, S or N atoms, or an aryl or heteroaryl group containing one to four heteroatoms selected from O, S or N, the saturated ring, aryl and heteroaryl groups all being optionally substituted by halogen, amino, hydroxy, cyano, nitro, carboxy, CONR⁷R⁸, SO₂NR⁷R⁸, SO₂R³, trifluoromethyl, NHSO₂R³, NHCOR³, C₁₋₆ alkyl, C₁₋₆ alkoxy, SR³ or NR⁹R¹⁰ where R⁹ and R¹⁰ are independently hydrogen, C₁₋₆ alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR³ group;

30

R^3 is hydrogen or C_{1-6} alkyl;

R^4 is hydrogen or C_{1-6} alkyl;

R^5 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl both of which can optionally contain one or more O, S or NR^3 groups or R^5 is aryl or a 5- or 6-membered heteroaryl group containing one or two heteroatoms selected from O, S or N, the aryl and heteroaryl groups all being optionally substituted by halogen, amino, hydroxy, cyano, nitro, carboxy, $CONR^7R^8$, $SO_2NR^7R^8$, SO_2R^3 , trifluoromethyl, $NHSO_2R^3$, $NHCOR^3$, C_{1-6} alkyl, C_{1-6} alkoxy, SR^3 or NR^9R^{10} where R^9 and R^{10} are independently hydrogen, C_{1-6} alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR^3 group;

or R^4 and R^5 together form a 5- or 6-membered saturated ring optionally containing a further O, S or NR^3 group and optionally substituted by, C_{1-6} alkyl;

and pharmaceutically acceptable salts or solvates thereof.

2. A compound according to claim 1 in which A is a cyclohexane ring.

3. A compound according to claim 1 or 2 in which R^1 and R^2 together with the nitrogen atom to which they are attached form an unsubstituted morpholine ring or a piperidine ring substituted by a group $-(CH_2)_p-R^6$ where p and R^6 are as defined in claim 1

4. A compound according to any one of claims 1 to 3 in which R^3 is hydrogen.

5. A compound according to any one of claims 1 to 4 in which R^4 is hydrogen.

6. A compound according to any one of claims 1 to 5 in which R^5 is hydrogen or phenyl optionally substituted by C_{1-6} alkyl or C_{1-6} alkoxy.

7. A compound of formula (I) selected from:

(1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(morpholin-4-ylcarbonyl)cyclohexanecarboxamide,

- (1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-[[4-(4-fluorobenzyl)piperazin-1-yl]carbonyl]cyclohexane carboxamide,
 (1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)cyclohexane carboxamide,
 5 (±) Trans-N-(cyanomethyl)-2-[[4-(4-fluorobenzyl)piperazin-1-yl]carbonyl]cyclohexanecarboxamide,
 (±) Trans-N-[cyano(2-methoxyphenyl)methyl]-2-[(4-methylpiperazin-1-yl)carbonyl]cyclohexanecarboxamide,
 (1R,2R)-N-[Cyano(2-methoxyphenyl)methyl]-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexane carboxamide,
 10 (1R,2R)-N-(4-Cyano-1-methylpiperidin-4-yl)-2-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]cyclohexane carboxamide,
 and pharmaceutically acceptable salts thereof.
- 15 8. A compound of formula (I) as defined in any one of claims 1 to 7 for use in therapy.
9. A pharmaceutical composition which comprises a compound of the formula (I) as defined in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.
- 20 10. A method for producing inhibition of a cysteine protease in a mammal, such as man, in need of such treatment, which comprises administering to said mammal an effective amount of a compound of the present invention as defined in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

ABSTRACT

The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of such inhibitors.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.